0001144204-14-059848.txt : 20141007 0001144204-14-059848.hdr.sgml : 20141007 20141007130100 ACCESSION NUMBER: 0001144204-14-059848 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20141007 FILED AS OF DATE: 20141007 DATE AS OF CHANGE: 20141007 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Galmed Pharmaceuticals Ltd. CENTRAL INDEX KEY: 0001595353 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981147233 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36345 FILM NUMBER: 141144985 BUSINESS ADDRESS: STREET 1: 8 SHAUL HAMELECH BLVD. STREET 2: AMOT HAMISHPAT BLDG. CITY: TEL AVIV STATE: L3 ZIP: 64733 BUSINESS PHONE: 97236938448 MAIL ADDRESS: STREET 1: 8 SHAUL HAMELECH BLVD. STREET 2: AMOT HAMISHPAT BLDG. CITY: TEL AVIV STATE: L3 ZIP: 64733 6-K 1 v390878_6k.htm 6-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934

 

For the Month of October 2014

 

001-36345
(Commission File Number)

 

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

 

8 Shaul Hamelech Blvd.

Amot Hamishpat Bldg.

Tel Aviv, Israel 64733

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.

 

Form 20-F þ Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): ¨

 

 
 

 

On October 7, 2014, Galmed Pharmaceuticals Ltd. (the “Company”) and Mr. Chanan Ray Morris mutually agreed to terminate that certain consulting agreement, dated March 4, 2014, pursuant to which Mr. Morris served as the Company’s Chief Financial Officer. The termination will be effective as of December 31, 2014 and Mr. Morris will continue to serve as the Company’s Chief Financial Officer through such date. Prior to year-end 2014, the Company currently anticipates appointing a permanent, full-time Chief Financial Officer to replace Mr. Morris, whose services would be effective as of January 1, 2015.

 

2
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Galmed Pharmaceuticals Ltd.
   
Date:  October 7, 2014 By: /s/ Allen Baharaff
    Allen Baharaff
    Chief Executive Officer